Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vermillion extends research collaboration with Quest Diagnostics
The Ova1 test is intended to identify women with ovarian tumors that are at high risk of being malignant. Data from a 27-site, 511 subject prospective clinical trial
The Ova1 test is intended to identify women with ovarian tumors that are at high risk of being malignant. Data from a 27-site, 511 subject prospective clinical trial
Under the terms of this agreement, sales of BiovaxID are expected to commence in the first calendar quarter of 2009, with the anticancer vaccine being made available to
On an intent-to-treat basis for the 125 enrolled patients, the median progression-free survival was 5.6 months on the Telcyta plus pegylated liposomal doxorubicin (PLD) arm compared to 3.7
Under the terms of the agreement, Theratechnologies will receive an upfront payment of $30 million which includes a license fee of $22 million and an equity investment of
ARC1905 represents one of three compounds that Ophthotech is developing to treat age-related macular degeneration (AMD). Additional molecular entities include E10030, an anti-PDGF aptamer currently in a Phase
Under the EU’s mutual recognition process, the company expects to receive renewal licenses for member states including Finland, Greece, Luxembourg, The Netherlands, Belgium, the UK and Portugal, over
Furthermore, the company announced that it will implement a strategic initiative to focus its resources on the clinical development of its proprietary pipeline. MethylGene will reacquire all rights
The Australian Patent Office has granted the company a patent that contains formulation and method claims to a pharmaceutical formulation comprising a macromolecular pharmaceutical agent in mixed micellar
The FDA has previously granted the product fast track designation and approved a rolling new drug application (NDA) submission schedule. The company has recently announced results of the
The planned expansion added a second freestanding 20,000 square feet building to the existing campus. The new $3.5 million facility houses SpectraCell’s clinical laboratory operations while the existing